Vinod H. Thourani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vinod H. Thourani has a total of 584 co-authors. Here are the top co-authors by number of shared publications:
J. James Edelman
Department of Cardiac Surgery, Fiona Stanley Hospital, Perth, Australia
26 shared publications- Samir R. Kapadia
Cleveland Clinic
19 shared publications Martin Leon
New York-Presbyterian/Columbia University Irving Medical Center, New York, New York, USA
17 shared publications- Susheel Kodali
New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York, United States
17 shared publications - Michael J. Mack
Baylor Scott and White Health, Plano, TX (M.J.M.).
14 shared publications - Maria C. Alu
Cardiovascular Research Foundation, New York, New York, USA
13 shared publications
Latest Publications
- Top Cited PapersOpen Access
10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis
- 11 June 2026
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 122 (2) , 370-371
Shortcuts and “the Way”: Management of Moderate Aortic Stenosis During Coronary Artery Bypass Grafting
- 11 June 2026
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 122 (2) , 370-371
Shortcuts and “the Way”: Management of Moderate Aortic Stenosis During Coronary Artery Bypass Grafting
- Open Access
- 1 March 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (3) , e015945
Hemodynamics and Mid-Term Clinical Outcomes Following Valve-in-Valve TAVR With Balloon-Expandable Valves
BACKGROUND: Lower (P =0.024). MG P <0.0001). Severe PPM and MG ≥20 mm Hg were not associated with worse 5-year outcomes compared with none/moderate PPM or MG ≤20 mm Hg, respectively. CONCLUSIONS: Discharge MG 20 mm Hg were not associated with worse 5-year clinical outcomes. Incorporating data on ejection fraction with PPM and MG is important before determining the need for valve optimization.
- 1 March 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (3) , e015945
Open AccessHemodynamics and Mid-Term Clinical Outcomes Following Valve-in-Valve TAVR With Balloon-Expandable Valves
BACKGROUND: Lower (P =0.024). MG P <0.0001). Severe PPM and MG ≥20 mm Hg were not associated with worse 5-year outcomes compared with none/moderate PPM or MG ≤20 mm Hg, respectively. CONCLUSIONS: Discharge MG 20 mm Hg were not associated with worse 5-year clinical outcomes. Incorporating data on ejection fraction with PPM and MG is important before determining the need for valve optimization.
- 3 December 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 121 (2) , 273-274
Stepping Stones and Surrogate End Points: Hemodynamic Valve Deterioration After Transcatheter Aortic Valve Replacement
- 3 December 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 121 (2) , 273-274
Stepping Stones and Surrogate End Points: Hemodynamic Valve Deterioration After Transcatheter Aortic Valve Replacement
- 29 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (17) , 2059-2073
Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
Background and Aims: The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. Methods: The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan–Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. Results: One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (−11.6, 11.9), massive/torrential −5.8% (−17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (−3.0, 22.7), massive/torrential -15.2% (−28.9, −1.5)]. Conclusions: Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.
- 29 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (17) , 2059-2073
Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
Background and Aims: The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. Methods: The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan–Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. Results: One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (−11.6, 11.9), massive/torrential −5.8% (−17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (−3.0, 22.7), massive/torrential -15.2% (−28.9, −1.5)]. Conclusions: Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.
- 16 December 2024
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 119 (3) , 555-566
Five- Year Outcomes in Low-Risk Patients Undergoing Surgery in the PARTNER 3 Trial
- 16 December 2024
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 119 (3) , 555-566
Five- Year Outcomes in Low-Risk Patients Undergoing Surgery in the PARTNER 3 Trial
- Open Access
- 9 December 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (23) , 2749-2760
Transcatheter Edge-to-Edge Repair in Patients With Complex Tricuspid Valve Anatomy
- 9 December 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (23) , 2749-2760
Open AccessTranscatheter Edge-to-Edge Repair in Patients With Complex Tricuspid Valve Anatomy
- 28 October 2024
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 119 (5) , 1035-1036
Looking Backward Helps Us Look Forward
- 28 October 2024
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 119 (5) , 1035-1036
Looking Backward Helps Us Look Forward
- Open Access
- 10 September 2024
- Published by Elsevier in JTCVS Open
- Vol. 22, 160-173
Five-year comparison of clinical and echocardiographic outcomes of pure aortic stenosis with pure aortic regurgitation or mixed aortic valve disease in the COMMENCE trial
- 10 September 2024
- Published by Elsevier in JTCVS Open
- Vol. 22, 160-173
Open AccessFive-year comparison of clinical and echocardiographic outcomes of pure aortic stenosis with pure aortic regurgitation or mixed aortic valve disease in the COMMENCE trial
- 18 June 2024
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 119 (1) , 145-151
Beyond Static Planning: Computational Predictive Modeling to Avoid Coronary Artery Occlusion in TAVR
- 18 June 2024
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 119 (1) , 145-151
Beyond Static Planning: Computational Predictive Modeling to Avoid Coronary Artery Occlusion in TAVR